In Vitro Antifungal Susceptibility Profile and Correlation of Mycelial and Yeast Forms of Molecularly Characterized Histoplasma capsulatum Strains from India

被引：16

作者：

Kathuria, Shallu ^{[1
]}

Singh, Pradeep K. ^{[1
]}

Meis, Jacques F. ^{[2
,3
]}

Chowdhary, Anuradha ^{[1
]}

机构：

[1] Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Med Mycol, Delhi 110007, India

[2] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6525 ED Nijmegen, Netherlands

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 09期

关键词：

DIMORPHIC FUNGI; AMPHOTERICIN-B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE; RESISTANCE; TRIAZOLES; L-743,872; AIDS;

D O I：

10.1128/AAC.02973-14

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The antifungal susceptibility profiles of the mycelial and yeast forms of 23 Histoplasma capsulatum strains from pulmonary and disseminated histoplasmosis patients in India are reported here. The MIC data of this dimorphic fungus had good agreement between both forms for azoles, amphotericin B, and caspofungin. Therefore, the use of mycelial inocula for H. capsulatum antifungal susceptibility testing is suggested, which is less time-consuming vis-a-vis the yeast form, which requires 6 to 8 weeks for conversion.

引用

页码：5613 / 5616

页数：4

共 27 条

[1]

[Anonymous], 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

[2]

Third Informational Supplement. CLSI document M27-S3, P28

[3] Histoplasmosis in HIV-positive patients in Ceara, Brazil: clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates [J].

Brilhante, Raimunda S. N. ;

Fechine, Maria A. B. ;

Mesquita, Jaco R. L. ;

Cordeiro, Rossana A. ;

Rocha, Marcos F. G. ;

Monteiro, Andre J. ;

Lima, Rita A. C. ;

Caetano, Erica P. ;

Pereira, Juliana F. ;

Castelo-Branco, Debora S. C. M. ;

Camargo, Zoilo P. ;

Sidrim, Jose J. C. .

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2012, 106 (08) :484-488

[4]

Clinical and Laboratory Standards Institute, 2008, M38A2 CLSI

[5]

Espinel-Ingroff, 2003, REV IBEROAM MICOL, V20, P121

[6] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202

[7] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956

[8] In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi [J].

Gonzalez, Gloria M. .

MEDICAL MYCOLOGY, 2009, 47 (01) :71-76

[9] In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi [J].

González, GM ;

Fothergill, AW ;

Sutton, DA ;

Rinaldi, MG ;

Loebenberg, D .

MEDICAL MYCOLOGY, 2005, 43 (03) :281-284

[10] Treatment of histoplasmosis with MK-991 (L-743,872) [J].

Graybill, JR ;

Najvar, LK ;

Montalbo, EM ;

Barchiesi, FJ ;

Luther, MF ;

Rinaldi, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :151-153

← 1 2 3 →